Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
Background Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic neoplasms and there is no well-elucidated biomarker to stratify their detection and prognosis. Previous studies have reported that progesterone receptor (PR) expression status was associated with poorer survi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society of Pathologists & the Korean Society for Cytopathology
2017-07-01
|
| Series: | Journal of Pathology and Translational Medicine |
| Subjects: | |
| Online Access: | http://www.jpatholtm.org/upload/pdf/jptm-2017-03-19.pdf |
| _version_ | 1828179824324116480 |
|---|---|
| author | Sung Joo Kim Soyeon An Jae Hoon Lee Joo Young Kim Ki-Byung Song Dae Wook Hwang Song Cheol Kim Eunsil Yu Seung-Mo Hong |
| author_facet | Sung Joo Kim Soyeon An Jae Hoon Lee Joo Young Kim Ki-Byung Song Dae Wook Hwang Song Cheol Kim Eunsil Yu Seung-Mo Hong |
| author_sort | Sung Joo Kim |
| collection | DOAJ |
| description | Background Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic neoplasms and there is no well-elucidated biomarker to stratify their detection and prognosis. Previous studies have reported that progesterone receptor (PR) expression status was associated with poorer survival in PanNET patients. Methods To validate previous studies, PR protein expression was assessed in 21 neuroendocrine microadenomas and 277 PanNETs and compared with clinicopathologic factors including patient survival. Results PR expression was gradually decreased from normal islets (49/49 cases, 100%) to neuroendocrine microadenoma (14/21, 66.6%) to PanNETs (60/277, 21.3%; p < .001). PanNETs with loss of PR expression were associated with increased tumor size (p < .001), World Health Organization grade (p = .001), pT classification (p < .001), perineural invasion (p = .028), lymph node metastasis (p = .004), activation of alternative lengthening of telomeres (p = .005), other peptide hormonal expression (p < .001) and ATRX/DAXX expression (p = .015). PanNET patients with loss of PR expression (5-year survival rate, 64.1%) had significantly poorer recurrence-free survival outcomes than those with intact PR expression (90%) by univariate (p = .012) but not multivariate analyses. Similarly, PanNET patients with PR expression loss (5-year survival rate, 76%) had significantly poorer overall survival by univariate (p = .015) but not multivariate analyses. Conclusions Loss of PR expression was noted in neuroendocrine microadenomas and was observed in the majority of PanNETs. This was associated with increased grade, tumor size, and advanced pT and pN classification; and was correlated with decreased patient survival time by univariate but not multivariate analyses. Loss of PR expression can provide additional information on shorter disease-free survival in PanNET patients. |
| first_indexed | 2024-04-12T05:36:05Z |
| format | Article |
| id | doaj.art-c7ffa0aba3724503b7a9c6d2d5204836 |
| institution | Directory Open Access Journal |
| issn | 2383-7837 2383-7845 |
| language | English |
| last_indexed | 2024-04-12T05:36:05Z |
| publishDate | 2017-07-01 |
| publisher | Korean Society of Pathologists & the Korean Society for Cytopathology |
| record_format | Article |
| series | Journal of Pathology and Translational Medicine |
| spelling | doaj.art-c7ffa0aba3724503b7a9c6d2d52048362022-12-22T03:45:53ZengKorean Society of Pathologists & the Korean Society for CytopathologyJournal of Pathology and Translational Medicine2383-78372383-78452017-07-0151438839510.4132/jptm.2017.03.1916696Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor PatientsSung Joo KimSoyeon AnJae Hoon Lee0Joo Young Kim1Ki-Byung Song2Dae Wook Hwang3Song Cheol Kim4Eunsil YuSeung-Mo Hong Division of Hepatobiliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea Division of Hepatobiliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Division of Hepatobiliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Division of Hepatobiliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaBackground Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic neoplasms and there is no well-elucidated biomarker to stratify their detection and prognosis. Previous studies have reported that progesterone receptor (PR) expression status was associated with poorer survival in PanNET patients. Methods To validate previous studies, PR protein expression was assessed in 21 neuroendocrine microadenomas and 277 PanNETs and compared with clinicopathologic factors including patient survival. Results PR expression was gradually decreased from normal islets (49/49 cases, 100%) to neuroendocrine microadenoma (14/21, 66.6%) to PanNETs (60/277, 21.3%; p < .001). PanNETs with loss of PR expression were associated with increased tumor size (p < .001), World Health Organization grade (p = .001), pT classification (p < .001), perineural invasion (p = .028), lymph node metastasis (p = .004), activation of alternative lengthening of telomeres (p = .005), other peptide hormonal expression (p < .001) and ATRX/DAXX expression (p = .015). PanNET patients with loss of PR expression (5-year survival rate, 64.1%) had significantly poorer recurrence-free survival outcomes than those with intact PR expression (90%) by univariate (p = .012) but not multivariate analyses. Similarly, PanNET patients with PR expression loss (5-year survival rate, 76%) had significantly poorer overall survival by univariate (p = .015) but not multivariate analyses. Conclusions Loss of PR expression was noted in neuroendocrine microadenomas and was observed in the majority of PanNETs. This was associated with increased grade, tumor size, and advanced pT and pN classification; and was correlated with decreased patient survival time by univariate but not multivariate analyses. Loss of PR expression can provide additional information on shorter disease-free survival in PanNET patients.http://www.jpatholtm.org/upload/pdf/jptm-2017-03-19.pdfPancreasNeuroendocrine tumorsReceptors, progesteroneSurvival |
| spellingShingle | Sung Joo Kim Soyeon An Jae Hoon Lee Joo Young Kim Ki-Byung Song Dae Wook Hwang Song Cheol Kim Eunsil Yu Seung-Mo Hong Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients Journal of Pathology and Translational Medicine Pancreas Neuroendocrine tumors Receptors, progesterone Survival |
| title | Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients |
| title_full | Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients |
| title_fullStr | Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients |
| title_full_unstemmed | Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients |
| title_short | Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients |
| title_sort | loss of progesterone receptor expression is an early tumorigenesis event associated with tumor progression and shorter survival in pancreatic neuroendocrine tumor patients |
| topic | Pancreas Neuroendocrine tumors Receptors, progesterone Survival |
| url | http://www.jpatholtm.org/upload/pdf/jptm-2017-03-19.pdf |
| work_keys_str_mv | AT sungjookim lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT soyeonan lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT jaehoonlee lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT jooyoungkim lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT kibyungsong lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT daewookhwang lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT songcheolkim lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT eunsilyu lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients AT seungmohong lossofprogesteronereceptorexpressionisanearlytumorigenesiseventassociatedwithtumorprogressionandshortersurvivalinpancreaticneuroendocrinetumorpatients |